(Q24193127)

title

Antibiotics for community-acquired pneumonia in adult outpatients (English)

0 references

0 references

0 references

3

Theo J M Verheij

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300166%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

5

Gernot G U Rohde

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300166%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Smita Pakhale

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300166%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Sunita Mulpuru

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300166%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Michael M Kochen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300166%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Lise M Bjerre

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300166%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

5 June 2020

publication date

9 October 2014

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300166%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

CD002109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300166%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300166%20AND%20SRC:MED&resulttype=core&format=json

Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group

5 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Clinical and economic burden of community-acquired pneumonia among adults in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Efficacy and safety of cefprozil versus other beta-lactam antibiotics in the treatment of lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Comparative study of azithromycin and amoxicillin/clavulanic acid in the treatment of lower respiratory tract infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Tobramycin for the treatment of bacterial pneumonia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Access to a polymerase chain reaction assay method targeting 13 respiratory viruses can reduce antibiotics: a randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Temafloxacin compared with ciprofloxacin in mild to moderate lower respiratory tract infections in ambulatory patients. A multicenter, double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Tigecycline versus levofloxacin in hospitalized patients with community-acquired pneumonia: an analysis of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Comparison of two oral antibiotics, roxithromycin and amoxicillin plus clavulanic acid, in lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Considerations of antibiotic therapy duration in community- and hospital-acquired bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Summary of ceftaroline fosamil clinical trial studies and clinical safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

A comparison of cefditoren pivoxil and amoxicillin/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: nested cohort within a multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Early switch therapy from intravenous sulbactam/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: a multicenter, randomized study in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Sparfloxacin as alternative treatment to standard therapy for community-acquired bacteremic pneumococcal pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

How to reduce antibiotic consumption for community-acquired pneumonia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. Nordic Atypical Pneumonia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

What is the role of antimicrobial stewardship in improving outcomes of patients with CAP?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia

21 January 2018

2 references

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

21 January 2018

12 December 2020

Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Systemic corticosteroids for community-acquired pneumonia: reasons for use and lack of benefit on outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Azithromycin versus comparative therapy for the treatment of community acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

A clinical comparative study of piperacillin and sulbactam/ampicillin in patients with community-acquired bacterial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Generic versus non-generic formulation of extended-release clarithromycin in patients with community-acquired respiratory tract infections: a prospective, randomized, comparative, investigator-blind, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Advances in antibiotic therapy for community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Update to the Latin American Thoracic Society (ALAT) Recommendations on Community-Acquired Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

2004 update of BTS pneumonia guidelines: what's new?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

BTS guidelines for the management of community acquired pneumonia in adults: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Comparative radiographic features of community acquired Legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia, and psittacosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Executive summary of the Gulf Cooperation Council practice guidelines for the management of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Severe Community-acquired Pneumonia: Epidemiology and Prognostic Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Prospective study of the aetiology and outcome of pneumonia in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Guidelines for the management of adult lower respiratory tract infections--full version

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Antibiotics for community acquired pneumonia in adult outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Antibiotics for community acquired pneumonia in adult outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB4

Assessment of the management of community-acquired pneumonia in adults outpatients

21 January 2018

1 reference

12 December 2020

Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin

1 reference

12 December 2020

Comparative tolerability, safety and efficacy of tablet formulations of twice-daily clarithromycin 250 mg versus once-daily extended-release clarithromycin 500 mg in pediatric and adolescent patients

1 reference

12 December 2020

A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia

1 reference

12 December 2020

[Management of adult patients with community-acquired pneumonia. Evidence-based guidelines from the Swedish Infectious Diseases Association]

1 reference

12 December 2020

Swedish guidelines on the management of community-acquired pneumonia in immunocompetent adults--Swedish Society of Infectious Diseases 2012

1 reference

12 December 2020

A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome

1 reference

12 December 2020

Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland

1 reference

12 December 2020

Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia

1 reference

12 December 2020

A comparative study of dirithromycin and erythromycin in bacterial pneumonia

1 reference

12 December 2020

A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections

1 reference

12 December 2020

A comparison of oral therapy with clindamycin and penicillin G in common gram-positive infections

1 reference

12 December 2020

A randomized double-blind controlled trial of roxithromycin and cefaclor in the treatment of acute lower respiratory tract infections in general practice

1 reference

12 December 2020

Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory tract infections

1 reference

12 December 2020

Comparison of spiramycin and doxycycline in the treatment of lower respiratory infections in general practice

1 reference

12 December 2020

Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia

1 reference

12 December 2020

Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia

1 reference

12 December 2020

Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study

1 reference

12 December 2020

Clarithromycin versus cefaclor in lower respiratory tract infections. The Canadian Bronchitis Study Group

1 reference

12 December 2020

Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults.

1 reference

12 December 2020

Randomized comparative study of ceftibuten versus cefaclor in the treatment of acute lower respiratory tract infections

1 reference

12 December 2020

Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group

1 reference

12 December 2020

Postdated versus usual delayed antibiotic prescriptions in primary care: Reduction in antibiotic use for acute respiratory infections?

1 reference

12 December 2020

Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia

1 reference

12 December 2020

Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis

1 reference

12 December 2020

Ofloxacin once daily versus twice daily in community-acquired pneumonia and acute exacerbation of chronic bronchitis. A randomized multicenter study

1 reference

12 December 2020

Comparison of Clarithromycin and Amoxicillin/Clavulanic Acid for Community-Acquired Pneumonia in an Era of Drug-Resistant Streptococcus pneumoniae

1 reference

12 December 2020

Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials

1 reference

12 December 2020

Guidelines of the Paul-Ehrlich-Society of Chemotherapy, the German Respiratory Diseases Society, the German Infectious Diseases Society and of the Competence Network CAPNETZ for the Management of Lower Respiratory Tract Infections and Community-acqu

1 reference

12 December 2020

Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group

1 reference

12 December 2020

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

1 reference

12 December 2020

SWAB/NVALT (Dutch Working Party on Antibiotic Policy and Dutch Association of Chest Physicians) guidelines on the management of community-acquired pneumonia in adults.

1 reference

12 December 2020

Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections

1 reference

12 December 2020

Guidelines for the management of community acquired pneumonia in adults, revised edition

1 reference

12 December 2020

Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults

1 reference

12 December 2020

Ertapenem versus ceftriaxone for the treatment of complicated infections: a meta-analysis of randomized controlled trials

1 reference

12 December 2020

Efficacy of twice-daily amoxycillin/clavulanate in lower respiratory tract infections

1 reference

12 December 2020

Comparison of spiramycin with erythromycin for lower respiratory tract infections.

1 reference

12 December 2020

A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia

1 reference

12 December 2020

Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections

1 reference

12 December 2020

ALAT (Latin American Thoracic Association) recommendations on community-acquired pneumonia

1 reference

12 December 2020

Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia

1 reference

12 December 2020

Comparison of amoxycillin and clarithromycin as initial treatment of community-acquired lower respiratory tract infections

1 reference

12 December 2020

Management of community-acquired pneumonia in adults

1 reference

12 December 2020

Procalcitonin-guided algorithms of antibiotic therapy in community-acquired lower respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials

1 reference

12 December 2020

10.1002/14651858.CD002109.PUB4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300166%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300166%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference